Burow oversees ARCH's participation in Remix Therapeutics $81M round
ARCH Venture Partners’ Kristina Burow oversees her firm’s investment in a developer of small molecule therapies designed to reprogram RNA processing to address the underlying drivers of disease. ARCH took part in Remix Therapeutics’ $81 million round, which also included Foresite Capital, Alexandria Venture Investments and seed investors Atlas Venture and The Column Group.
Based in Cambridge, Mass., Remix will use the capital to support development of its technology platform and advance a pipeline of RNA processing targeted therapeutics. In conjunction with the financing, Kristina joins Remix’s board as an observer.
Kristina, a managing director with ARCH, in 2020 has also backed Dewpoint Therapeutics, Autobahn Therapeutics and ROME Therapeutics, whose CEO, president and co-founder is Dr. Rosana Kapeller. Kristina is on the boards of all three companies and also on the boards of Vividion Therapeutics, Epirium Bio, Inc., Lycera, BlackThorn Therapeutics, Llama Therapeutics, AgBiome, AgTech Accelerator, Boundless Bio and seven other publicly traded companies: Sienna Biopharmaceuticals, Scholar Rock, Unity Biotechnology, Beam Therapeutics, Metacrine, Inc., Vir Biotechnology and Gossamer Bio, Inc., whose CEO is Dr. Sheila Gujrathi. Beam and Metacrine went public this year while Vir and Gossamer went public last year.